A renaissance of interest in innate immunity: Will new treatments for rheumatoid arthritis emerge?

Future Rheumatology

Volumn 3, Issue 3, 2008, Pages 203-205

  O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROSTAGLANDIN; RITUXIMAB; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ANTIBODY;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 47249147532     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.3.203     Document Type: Editorial

References (17)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P: New therapies for rheumatoid arthritis. Lancet 371, 1861-1874 (2007).
2. O'Neill LA: Immunity's early warning system. Sci. Am. 292, 38-45 (2005).
3. Creagh E, O'Neill LA: TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 27(8), 352-357 (2006).
4. Beutler B: Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257-263 (2004).
5. Erickson AR, Mikuls TR: Switching anti-TNF-α agents: what is the evidence. Curr. Rheumatol. Rep. 9, 416-420 (2007).
6. Mariette X, Ravaud P, Steinfeld S et al.: Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized controlled trial of Remicade in primary Sjogren's syndrome. Arthritis Rheum. 50, 1270-1276 (2004).
7. Muller T, Hamm S, Bauer S: TLR9-mediated recognition of DNA. Handb. Exp. Pharmacol. 183, 51-70 (2008).
8. Jiang D, Liang J, Noble PW: Hyaluronan in tissue injury and repair. Annu. Rev. Cell. Dev. Biol. 23, 435-461 (2007).
9. Inohara N, Chamaillard M, McDonald C, Nuñez G: NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355-383 (2005).
10. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 228-232 (2006).
11. Matzinger P: The danger model: a renewed sense of self. Science 296, 301-305 (2002).
12. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G: TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124-1136 (2007).
13. An H, Hou J, Zhou J et al.: Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 9 (5), 542-550 (2008).
14. McDermott MF, Tschopp J: From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends Mol. Med. 13, 381-388 (2007).
15. Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1 recetor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583-2584 (2003).
16. Dinarello CA: Historical insights into cytokines. Eur. J. Immunol. 37(Suppl. 1), S34-S45 (2007).
17. Stanczyk J, Pedrioli DM, Brentano F et al.: Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 58, 1001-1009 (2008).